(lp0
S"ArQule, Inc.  Shares Dive as HCC Trial Fails to Meet Primary Endpoint Smarter Analyst - Feb 17, 2017 ArQule, Inc.  shares tumbled nearly 20% this morning after investors learned that the company's METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma  did not meet its primary endpoint of improving overall survival."
p1
aS'1.22 MarketWatch - Oct 31, 2010 ArQule Inc. ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of pharmaceutical products.'
p2
aS'ArQule Is Undervalued Going Into Catalyst Events Seeking Alpha - Oct 21, 2016 ArQule  is a small biopharmaceutical company  engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.'
p3
aS'Breaking Down: ArQule Inc  Stock Drop Below Support -- Technicals ... CML News - 14 hours ago Breaking Down: ArQule Inc  has hit extreme technical weakness -- watch the stochastics and technical oscillators for any kind of momentum signals if you are looking for a turnaround.'
p4
aS"ArQule, Inc. 's Liver Cancer Drug Fails: What's Next? Market Exclusive - Feb 20, 2017 ArQule, Inc.  took a real hit at the end of last week, as the company announced data from a late stage oncology trial.Two Stocks on Trader's Radar: ArQule Inc. , Dean Foods Company ... - The Newburgh Press"
p5
aS'Stock Overview: Moving Average Check on ArQule Inc  Providence Standard - 10 hours ago Narrowing in on moving averages for ArQule Inc , the 200-day is at 1.49, the 50-day is 1.38, and the 7-day is resting at 1.22.'
p6
aS'Annual Global Healthcare Conference on February 15, 2017 Business Wire  - Feb 8, 2017 BURLINGTON, Mass.----ArQule, Inc.  today announced that Paolo Pucci, Chief Executive Officer, and Dr.'
p7
aS'ArQule Reports Fourth Quarter and Full Year 2016 Financial Results Yahoo Finance - Mar 7, 2017 ArQule, Inc.  today announced its financial results for the fourth quarter and full year of 2016. For the quarter ended December 31, 2016, the Company reported a net loss of $6,820,000 or $0.10 per share, compared with net loss of $2,852,000 or ...'
p8
aS"Sell-Side Analyst's Predictions: ArQule, Inc. , Array BioPharma Inc.  The USA Commerce - Feb 21, 2017 Shares of ArQule, Inc.  dropped -18.37% to $1.20. During the trading on 02/17/2017, Company's stock ranged from $1.13 to $1.26."
p9
aS"Important Detailed Discussion about ArQule, Inc.'s  stock price is now ... Hot Stocks Point - Mar 18, 2017 USA based company, ArQule, Inc. 's latest closing price distance was at -18.55% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -11.56% and -3.25% compared with the 20 Day Moving Average."
p10
a.